Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | AHR | P35869 | 3/20 | 0.37 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | HTR2C | P28335 | 3/20 | 0.36 |
| ▸ | HTR2B | P41595 | 3/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | FADS1 | O60427 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8800450 | 0.90 | MAOA (0.38) | MAOAMAOBFTONFKB1CYP2A6 | |
| SCHEMBL6478330 | 0.77 | DYRK1A (0.38) | MAOAMAOBFTONFKB1HTR2A | |
| SCHEMBL14824860 | 0.77 | HTR2A (0.38) | MAOAMAOBFTONFKB1HTR2A | |
| SCHEMBL5497618 | 0.77 | CYP3A4 (0.39) | MAOAMAOBFTONFKB1CYP2A6 | |
| SCHEMBL6921642 | 0.77 | MAOA (0.38) | MAOAMAOBFTONFKB1HTR2A | |
| SCHEMBL6949814 | 0.77 | MAOA (0.38) | MAOAMAOBFTONFKB1HTR2A | |
| SCHEMBL4429415 | 0.76 | PAX8 (0.48) | MAOAMAOBFTONFKB1CYP2A6 | |
| SCHEMBL8800180 | 0.75 | CYP1A1 (0.31) | CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL12533388 | 0.73 | MAOA (0.34) | MAOAMAOBFTONFKB1HTR2A | |
| SCHEMBL6955842 | 0.73 | MAOA (0.34) | MAOAMAOBFTONFKB1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3912977-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BioMarin Pharmaceutical Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3046920-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-10927092-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARM INC (US) | 2021-02-23 | — | — | US | disclosed |
| US-20190263775-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2019-08-29 | — | — | US | disclosed |
| US-10227323-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2016-08-11 | — | — | US | disclosed |
| WO-2015042397-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| EP-0758333-A1 | INTERMEDIATES IN PHARMACEUTICAL CAMPTOTHECIN PREPARATION | GLAXO WELLCOME INC. (US) | 1997-02-19 | — | — | EP | disclosed |
| EP-0355827-B1 | Hydantoin derivatives | MOCHIDA PHARM CO LTD (JP) | 1997-01-02 | — | — | EP | disclosed |
| US-RE35279-E | ALDOSE REDUCTASE INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1996-06-18 | — | — | US | disclosed |
| WO-1995029917-A2 | INTERMEDIATES IN PHARMACEUTICAL CAMPTOTHECIN PREPARATION | GLAXO WELLCOME INC. (US) | 1995-11-09 | — | — | WO | disclosed |
| US-5202339-A | Hypoglycemic, hypolipedemic agents | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1993-04-13 | — | — | US | disclosed |
| US-5004751-A | Antidiabetic agents; aldoe reductase inhibitors | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1991-04-02 | — | — | US | disclosed |
| WO-1990002126-A1 | HYDANTOIN DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1990-03-08 | — | — | WO | disclosed |
| EP-0355827-A2 | Hydantoin derivatives | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927092-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | MAOA 1303/4885MAOB 989/4885FTO 3051/4885 |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | MAOA 1303/4885MAOB 989/4885FTO 3051/4885 |
| US-10227323-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | MAOA 1303/4885MAOB 989/4885FTO 3051/4885 |
| US-20190263775-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | MAOA 1303/4885MAOB 989/4885FTO 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.